Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355798
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355798
Non-Small Cell Lung Cancer - Targeted Therapies - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Which combination strategies do KOLs say are likely to expand use of AstraZeneca's dominant EGFR TKI therapy Tagrisso? How do KOLs assess the potential of Genmab/Janssen's Rybrevant + Janssen's Leclaza in patients with EGFR-TKI resistance? Do KOLs believe the Phase III DESTINY-Lung04 study could establish Daiichi Sankyo/AstraZeneca's ADC Enhertu as a first-line therapy? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.
- 15 Sep 2023 KOL Bulletin -- Views on Phase III ALINA data for Roche's Alecensa
- 21 Sep 2023 KOL Bulletin -- Views on Phase III FLAURA2 data for AstraZeneca's Tagrisso
Table of Contents
Executive summary (6)
Current and future treatment algorithm
Research objectives (2)
EGFR and HER2 inhibitors (46)
- Approved and pipeline drugs (31)
- Tagrisso (osimertinib; AstraZeneca) (13)
- Rybrevant (amivantamab-vmjw; Genmab/Janssen) and Leclaza (lazertinib; Janssen) (12)
- Exkivity (mobocertinib; Takeda) (6)
- Pipeline drugs (15)
- Aumolertinib (Jiangsu Hansoh Pharmaceutical) (8)
- Pyrotinib (Jiangsu Hengrui Pharmaceuticals) (7)
Antibody-drug conjugates (31)
- Approved drugs (10)
- Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca) (10)
- Pipeline therapies (21)
- Trodelvy (sacituzumab govitecan; Gilead) and datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo) (7)
- Patritumab deruxtecan (Daiichi Sankyo) (5)
- Tusamitamab ravtansine (Sanofi) (5)
- Telisotuzumab vedotin (AbbVie) (4)
ALK inhibitors (12)
- Approved therapies (7)
- Alecensa (alectinib; Roche), Alunbrig (brigatinib; Takeda) and Lorbrena/Lorviqua (lorlatinib; Pfizer) (7)
- Pipeline therapies (5)
- Ensartinib (Betta Pharmaceuticals/Xvocery) (5)
KRAS inhibitors (21)
- Approved drugs (16)
- Lumakras/Lumykras (sotorasib; Amgen) (10)
- Krazati (adagrasib; Mirati Therapeutics) (6)
- Pipeline therapies (5)
- JDQ443 (Novartis) (5)
MET inhibitors (15)
- Approved drugs (8)
- Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group) (8)
- Pipeline therapies (7)
- Savolitinib (AstraZeneca/Hutchmed) (7)
RET inhibitors (8)
- Approved drugs (8)
- Gavreto (pralsetinib; Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly) (8)
Future treatment trends (8)
- Key insights summary (8)
Appendix (4)
- KOL details (4)
- KOLs from the USA (1)
- KOLs from Europe (2)
News (2)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.